A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors

Albert Lockhart, Emiliano Calvo, Anthony W. Tolcher, Eric K. Rowinsky, Gareth Shackleton, J. Gilmour Morrison, Rezvan Rafi, Wendy VerMeulen, Mace L. Rothenberg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase I study were to determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, pharmacokinetic profile, and trend for efficacy in patients with advanced cancer. Methods: SR271425 was administered intravenously over 1-hour, weekly for 2 weeks, followed by 1 week rest. Because of Cmax-related corrected QT (QTc) prolongation in preclinical testing of SR271425, all patients underwent an extensive pretreatment cardiac assessment. Results: Eighteen patients received SR271425 at 5 dose levels ranging from 64 to 675 mg/m2/wk. No dose-limiting toxicities were identified. In all tested dose-levels, Grade 3 adverse events were observed in 10/18 patients (55.6%) and Grade 4 in 4/18 patients (22.2%). QTc prolongation was reported at the 3 highest dose levels but did not exceed Grade 2. Six deaths occurred during the study, 5 of them because of disease progression and 1 because of disease related bowel perforation. SR271425 exposure increased in a near dose-proportional manner. The mean terminal plasma half-life of SR271425 was 6 hours and there was no drug accumulation after repeated dosing. Stable disease was the best outcome observed (5 patients). Conclusions: SR271425 was administered safely at doses up to 675 mg/ m2/wk on a 2-week on, 1-week off schedule. No dose-limiting toxicities were observed. Grade 2 QTc prolongation was observed at the highest dose levels. Maximum tolerated dose was not reached because of early termination of the SR271425 program by the sponsor.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume32
Issue number1
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Neoplasms
Maximum Tolerated Dose
SR 271425
thioxanthone
Half-Life
Disease Progression
Appointments and Schedules
Pharmacokinetics
DNA
Pharmaceutical Preparations

Keywords

  • Clinical trial
  • Phase I
  • Prolongation
  • Qt
  • SR271425
  • Thioxanthone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. / Lockhart, Albert; Calvo, Emiliano; Tolcher, Anthony W.; Rowinsky, Eric K.; Shackleton, Gareth; Morrison, J. Gilmour; Rafi, Rezvan; VerMeulen, Wendy; Rothenberg, Mace L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 32, No. 1, 01.02.2009, p. 9-14.

Research output: Contribution to journalArticle

Lockhart, Albert ; Calvo, Emiliano ; Tolcher, Anthony W. ; Rowinsky, Eric K. ; Shackleton, Gareth ; Morrison, J. Gilmour ; Rafi, Rezvan ; VerMeulen, Wendy ; Rothenberg, Mace L. / A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2009 ; Vol. 32, No. 1. pp. 9-14.
@article{fcff23448941434aa04f327ce58ff34e,
title = "A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors",
abstract = "Objectives: The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase I study were to determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, pharmacokinetic profile, and trend for efficacy in patients with advanced cancer. Methods: SR271425 was administered intravenously over 1-hour, weekly for 2 weeks, followed by 1 week rest. Because of Cmax-related corrected QT (QTc) prolongation in preclinical testing of SR271425, all patients underwent an extensive pretreatment cardiac assessment. Results: Eighteen patients received SR271425 at 5 dose levels ranging from 64 to 675 mg/m2/wk. No dose-limiting toxicities were identified. In all tested dose-levels, Grade 3 adverse events were observed in 10/18 patients (55.6{\%}) and Grade 4 in 4/18 patients (22.2{\%}). QTc prolongation was reported at the 3 highest dose levels but did not exceed Grade 2. Six deaths occurred during the study, 5 of them because of disease progression and 1 because of disease related bowel perforation. SR271425 exposure increased in a near dose-proportional manner. The mean terminal plasma half-life of SR271425 was 6 hours and there was no drug accumulation after repeated dosing. Stable disease was the best outcome observed (5 patients). Conclusions: SR271425 was administered safely at doses up to 675 mg/ m2/wk on a 2-week on, 1-week off schedule. No dose-limiting toxicities were observed. Grade 2 QTc prolongation was observed at the highest dose levels. Maximum tolerated dose was not reached because of early termination of the SR271425 program by the sponsor.",
keywords = "Clinical trial, Phase I, Prolongation, Qt, SR271425, Thioxanthone",
author = "Albert Lockhart and Emiliano Calvo and Tolcher, {Anthony W.} and Rowinsky, {Eric K.} and Gareth Shackleton and Morrison, {J. Gilmour} and Rezvan Rafi and Wendy VerMeulen and Rothenberg, {Mace L.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1097/COC.0b013e318178331b",
language = "English (US)",
volume = "32",
pages = "9--14",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors

AU - Lockhart, Albert

AU - Calvo, Emiliano

AU - Tolcher, Anthony W.

AU - Rowinsky, Eric K.

AU - Shackleton, Gareth

AU - Morrison, J. Gilmour

AU - Rafi, Rezvan

AU - VerMeulen, Wendy

AU - Rothenberg, Mace L.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Objectives: The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase I study were to determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, pharmacokinetic profile, and trend for efficacy in patients with advanced cancer. Methods: SR271425 was administered intravenously over 1-hour, weekly for 2 weeks, followed by 1 week rest. Because of Cmax-related corrected QT (QTc) prolongation in preclinical testing of SR271425, all patients underwent an extensive pretreatment cardiac assessment. Results: Eighteen patients received SR271425 at 5 dose levels ranging from 64 to 675 mg/m2/wk. No dose-limiting toxicities were identified. In all tested dose-levels, Grade 3 adverse events were observed in 10/18 patients (55.6%) and Grade 4 in 4/18 patients (22.2%). QTc prolongation was reported at the 3 highest dose levels but did not exceed Grade 2. Six deaths occurred during the study, 5 of them because of disease progression and 1 because of disease related bowel perforation. SR271425 exposure increased in a near dose-proportional manner. The mean terminal plasma half-life of SR271425 was 6 hours and there was no drug accumulation after repeated dosing. Stable disease was the best outcome observed (5 patients). Conclusions: SR271425 was administered safely at doses up to 675 mg/ m2/wk on a 2-week on, 1-week off schedule. No dose-limiting toxicities were observed. Grade 2 QTc prolongation was observed at the highest dose levels. Maximum tolerated dose was not reached because of early termination of the SR271425 program by the sponsor.

AB - Objectives: The thioxanthone analog, SR271425, is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models. The objectives of this phase I study were to determine the dose-limiting toxicities, maximum tolerated dose, recommended phase II dose, pharmacokinetic profile, and trend for efficacy in patients with advanced cancer. Methods: SR271425 was administered intravenously over 1-hour, weekly for 2 weeks, followed by 1 week rest. Because of Cmax-related corrected QT (QTc) prolongation in preclinical testing of SR271425, all patients underwent an extensive pretreatment cardiac assessment. Results: Eighteen patients received SR271425 at 5 dose levels ranging from 64 to 675 mg/m2/wk. No dose-limiting toxicities were identified. In all tested dose-levels, Grade 3 adverse events were observed in 10/18 patients (55.6%) and Grade 4 in 4/18 patients (22.2%). QTc prolongation was reported at the 3 highest dose levels but did not exceed Grade 2. Six deaths occurred during the study, 5 of them because of disease progression and 1 because of disease related bowel perforation. SR271425 exposure increased in a near dose-proportional manner. The mean terminal plasma half-life of SR271425 was 6 hours and there was no drug accumulation after repeated dosing. Stable disease was the best outcome observed (5 patients). Conclusions: SR271425 was administered safely at doses up to 675 mg/ m2/wk on a 2-week on, 1-week off schedule. No dose-limiting toxicities were observed. Grade 2 QTc prolongation was observed at the highest dose levels. Maximum tolerated dose was not reached because of early termination of the SR271425 program by the sponsor.

KW - Clinical trial

KW - Phase I

KW - Prolongation

KW - Qt

KW - SR271425

KW - Thioxanthone

UR - http://www.scopus.com/inward/record.url?scp=60549092154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549092154&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e318178331b

DO - 10.1097/COC.0b013e318178331b

M3 - Article

C2 - 19194116

AN - SCOPUS:60549092154

VL - 32

SP - 9

EP - 14

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -